The US indapamide market is estimated to grow significantly during the forecast period. The significant prevalence of hypertension along with the CVD and high healthcare expenditure is primarily contributing to the market growth in the region. According to the Center for Medicare and Medicaid Services, in 2018, the US national healthcare expenditure was around $3.6 trillion showing a 4.4% increase in healthcare expenditure up from 3.9% in 2017. It is further expected to reach $6.0 trillion by 2027. The US has the highest healthcare spending across the globe. CVD and strokes accounted for 14% of the total healthcare expenditure. Around 1 in 19 mortalities in the US were due to stroke in the country in 2017 causing more than 146,000 mortalities. In the US, the per capita healthcare expenditure per person in 2018 was around $10,800. Thus, high expenditure is likely to support the growth of the market. 

The US indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

The companies which are contributing to the growth of the US indapamide market include ANI Pharmaceuticals, Inc., Apotex Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Mylan N.V., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the US indapamide market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for indapamide market players, potential entrants and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. US Indapamide Market Research and Analysis by Product
2. US Indapamide Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the US indapamide market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the US indapamide market.
• Insights about market determinants which are stimulating the US indapamide market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.